Literature DB >> 23267748

Secondary and tertiary hyperparathyroidism.

Sophie A Jamal1, Paul D Miller.   

Abstract

We reviewed the etiology and management of secondary and tertiary hyperparathyroidism. Secondary hyperparathyroidism is characterized by an increase in parathyroid hormone (PTH) that is appropriate and in response to a stimulus, most commonly low serum calcium. In secondary hyperparathyroidism, the serum calcium is normal and the PTH level is elevated. Tertiary hyperparathyroidism is characterized by excessive secretion of PTH after longstanding secondary hyperparathyroidism, in which hypercalcemia has ensued. Tertiary hyperparathyroidism typically occurs in men and women with chronic kidney disease usually after kidney transplant. The etiology and treatment of secondary hyperparathyroidism is relatively straightforward whereas data on the management of tertiary hyperparathyroidism is limited to a few small trials with short follow-up.
Copyright © 2013 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23267748     DOI: 10.1016/j.jocd.2012.11.012

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  12 in total

1.  Clinical value of calcium load test in differential diagnosis of different types of hyperparathyroidism.

Authors:  Xiaoxiao Zhu; Chang Shan; Qi Zhu; Lige Song; Yun Zhou; Jia Liu; Keqin Zhang
Journal:  Int J Clin Exp Med       Date:  2014-11-25

2.  Invited Commentary: Calcinosis cutis and renal disease: an evolving story.

Authors:  Andrew Z Fenves; Daniela Kroshinsky
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

Review 3.  Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.

Authors:  Kerstin Lorenz; Detlef K Bartsch; Juan J Sancho; Sebastien Guigard; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2015-10-02       Impact factor: 3.445

4.  Safety and effectiveness of reoperation for persistent or recurrent drug refractory secondary hyperparathyroidism.

Authors:  Lei Zhu; Feng Cheng; Xi Zhu; Bin Zhou; Yonghong Xu; Yong Wu; Chuxiao Shao
Journal:  Gland Surg       Date:  2020-04

5.  Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome.

Authors:  Bo-Lin Pan; Song-Seng Loke
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

Review 6.  Review on the Utility of Trabecular Bone Score, a Surrogate of Bone Micro-architecture, in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients.

Authors:  Enisa Shevroja; Olivier Lamy; Didier Hans
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-24       Impact factor: 5.555

7.  Association between renal function and bone mineral density in healthy postmenopausal Chinese women.

Authors:  Shuang Li; Junkun Zhan; Yanjiao Wang; Yi Wang; Jieyu He; Wu Huang; Zhifeng Sheng; Youshuo Liu
Journal:  BMC Endocr Disord       Date:  2019-12-26       Impact factor: 2.763

8.  Sudden onset of parathyroid hormone-independent severe hypercalcemia from reversal of tumoral calcinosis in a dialysis patient.

Authors:  Fareed B Kamar; Bikaramjit Mann; Gregory Kline
Journal:  BMC Nephrol       Date:  2016-09-29       Impact factor: 2.388

9.  International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study.

Authors:  Kevin Chan; Angelo Karaboyas; Hal Morgenstern; Bruce M Robinson; Friedrich K Port; Stefan H Jacobson; Masafumi Fukagawa; Yvonne Meier; Philipp A Csomor; Ronald L Pisoni
Journal:  Kidney Med       Date:  2019-05-10

10.  Incidence of and risk factors for post-parathyroidectomy hungry bone syndrome in patients with secondary hyperparathyroidism.

Authors:  Kittrawee Kritmetapak; Sawinee Kongpetch; Wijittra Chotmongkol; Yutapong Raruenrom; Sakkarn Sangkhamanon; Chatlert Pongchaiyakul
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.